Drugs / MK-8457
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 missed | ||||||
| Phase 1 | NCT01446003 | Oct 2011 → Feb 2012 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT01651936 | Aug 2012 → Oct 2013 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 2 | NCT01569152 | May 2012 → Oct 2013 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8457 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01651936 ↗ |
| Modality | Small molecule | — CHEMBL3685811 ↗ |
| Route | Oral | “dosed orally BID” NCT01569152 ↗ |